Bulletin
Investor Alert

London Markets Open in:

Dec. 1, 2020, 2:20 a.m. EST

AstraZeneca to sell Crestor rights in Europe

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Adria Calatayud

AstraZeneca PLC said Tuesday that it has agreed to sell rights to its Crestor and associated medicines in over 30 countries in Europe to Gruenenthal GmbH in a deal worth up to $350 million.

The U.K. pharmaceutical giant said the deal excludes the U.K. and Spain. The company will continue selling the medicine in other areas, including North America, Japan, China and other emerging markets.

Crestor is used to treat blood lipid disorders and to prevent cardiovascular events such as heart attacks and strokes.

AstraZeneca said it will receive an upfront, non-contingent payment of $320 million and may receive future milestone payments of up to $30 million.

The divestment is anticipated to close in the first quarter of 2021 and won't affect the AstraZeneca's guidance for 2020, it said.

AstraZeneca will continue to manufacture and supply Crestor to Grunenthal during a transition period.

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.